Alan Crane is a general partner at Polaris Partners, focusing on building and investing in healthcare companies since 2002. He has served as founder and/or has played a significant role as chairman and chief executive officer (CEO) in the building of six Polaris companies. From 2006 to present, Mr. Crane co-founded and served as CEO of Cerulean Pharma (a public clinical-stage nanopharmaceutical company), co-founded Navitor Pharmaceuticals, co-founded Visterra (a company with novel technology targeting infectious disease) and co-founded XTuit Pharmaceuticals (a company developing tumor microenvironment drugs). From 2002 to 2006, he was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built the company into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis, and raising $275 million. The first product from Momenta's pipeline achieved over $1B during its first year of sales.
Prior to Polaris, Mr. Crane was Senior Vice President of global corporate development at Millennium Pharmaceuticals. He was responsible for leading Millennium's strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development-stage products, including Velcade® that became the main basis of the company's $9B acquisition by Takeda. In addition to serving as Chairman of Navitor, he serves on the boards of Cerulean Pharma (Chairman), T2 Biosystems, Ocular Therapeutix, Seventh Sense Biosystems, XTuit Pharmaceuticals (Chairman), and Vaccinex. Previously, he served on the boards of Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline) and Adnexus (acquired by Bristol-Myers Squibb).
Mr. Crane received his MBA in 1992, and his BA summa cum laude and MA in 1986, all from Harvard University. He also attended Harvard Medical School, from 1986 to 1988, before pursuing a business career.